3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
14
Thoracic
4
Head & Neck
4
Lymphoid
3
Gynecologic
3
Genitourinary
3
Gastrointestinal
3
Breast
3
Sarcoma
2
CNS
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Endocrine
1
Conditions
Sarcoma
7
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Thyroid Neoplasms
3
Thyroid Cancer, Papillary
3
Salivary Gland Neoplasms
3
Head and Neck Neoplasms
3
Gastrointestinal Stromal Tumors
3
Central Nervous System Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Thyroid Diseases
2
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Neoplasms by Site
2
Melanoma
2
Medulloblastoma
2
Lung Neoplasms
2
Lung Diseases
2
Glioma
2
Endocrine System Diseases
2
Endocrine Gland Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Interventions
larotrectinib
1
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Melanoma
×
Sarcoma
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA